Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.38 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926581 | 0.84 | CA1 (0.48) | P2RX7POLB | |
| SCHEMBL9926555 | 0.82 | MEP1B (0.41) | P2RX7KMT2AMEP1BMEP1A | |
| SCHEMBL9926557 | 0.81 | CXCL8 (0.41) | — | |
| SCHEMBL9926575 | 0.81 | POLB (0.44) | P2RX7KMT2APOLB | |
| SCHEMBL9926620 | 0.81 | HPGD (0.49) | P2RX7 | |
| SCHEMBL9926570 | 0.81 | SMN1; SMN2 (0.54) | TP53KMT2APOLB | |
| SCHEMBL9926664 | 0.81 | CYP1A2 (0.49) | KMT2A | |
| SCHEMBL9926537 | 0.81 | KDM4E (0.54) | P2RX7 | |
| SCHEMBL9926662 | 0.80 | ICMT (0.38) | P2RX7 | |
| SCHEMBL9926670 | 0.80 | PIK3CD (0.40) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | P2RX7 3259/4885TP53 3/4885KMT2A 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.